Sunitinib-containing carborane pharmacophore with the ability to inhibit tyrosine kinases receptors FLT3, KIT and PDGFR-β, exhibits powerful in vivo anti-glioblastoma activity

Malignant gliomas are the most common malignant and aggressive primary brain tumors in adults, the prognosis being—especially for glioblastomas—extremely poor. There are no effective treatments yet. However, tyrosine kinase receptor (TKR) inhibitors and boron neutron capture therapy (BNCT), together...

Celý popis

Podrobná bibliografie

Hlavní autor:	Alamón, Catalina (author)
Další autoři:	Dávila Saralegui, Belén (author), García Melián, María Fernanda (author), Sánchez, Carina (author), Kovacs, Mariángeles (author), Trias, Emiliano (author), Barbeito, Luis (author), Gabay, Martín (author), Zeineh, Nidal (author), Gavish, Moshe (author), Teixidor, Francesc (author), Viñas, Clara (author), Couto, Marcos (author), Cerecetto, Hugo (author)
Médium:	article
Jazyk:	angličtina
Vydáno:	2020
Témata:	Carborane FLT3 Sub-G1 arrest Anti-tumor activity
On-line přístup:	https://hdl.handle.net/20.500.12008/31990
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!